or
Remember me
Back
The pandemic is driving a growing unmet need when it comes to addressing the dramatic impact of sepsis deaths, which is still the #1 complication causing death among COVID-19 patients. Across overall statistics, sepsis kills over 11M people per year with 1:5 afflicted with sepsis dying to it.
There’s a seriously massive opportunity with ASEP Medical Holdings operating across their subsidiaries ABT Innovations and Sepset Biosciences who are developing and testing a treatment for biofilms which account for 65% of all bacterial infections causing Sepsis in addition to a rapid test to accurately identify severe sepsis, saving many more lives.
Receive investor kits and email updates from Stockhouse and directly from these companies.
